149816例接受无干扰素方案治疗的埃及慢性丙型肝炎患者的不良反应
这项多中心回顾性研究纳入149816例接受无干扰素直接抗病毒药物(DAA)方案治疗的埃及慢性丙型肝炎患者,评估治疗期间及之后的不良反应。不良反应发生率为1.7%(2475例),其中68%为严重不良反应,SOF/RBV方案最常见(73%,P<0.001);贫血和高胆红素血症最常见,SOF/RBV发生率最高。SOF/DCV方案不良反应最少。
要点
- 149816例中2475例(1.7%)出现不良反应,其中68%为严重不良反应。
- SOF/RBV方案引起不良反应的比例最高(73%,P<0.001),SOF/DCV方案最低。
- 贫血(731/149816,0.5%)和高胆红素血症(463/149816,0.3%)是最常见的不良反应。
核心结论
- DAA相关不良反应较少,贫血最常见;SOF/RBV方案不良反应发生率最高,SOF/DCV方案最低。
研究设计与样本
- 多中心回顾性研究,纳入149816例接受DAA方案治疗的埃及慢性丙型肝炎患者。
- 治疗方案包括SOF/RBV(n=21835)、SOF/simeprevir(n=24215)、SOF/DCV(n=58477)、SOF/DCV/RBV(n=45188)和paritaprevir/ombitasvir/ritonavir/RBV(n=101)。
- 治疗 duration 为12至24周。
主要发现
- 2475例(1.7%)出现不良反应,平均年龄54±9岁,男性占53%。
- 68%的不良反应为严重不良反应,SOF/RBV是最常见的致严重不良反应方案(73%,P<0.001)。
- 贫血发生率为731/149816(0.5%),高胆红素血症为463/149816(0.3%);SOF/RBV组贫血588/21835(3%)、高胆红素血症353/21835(1.6%),发生率最高。
- 肝细胞癌和死亡率分别为所有治疗患者的0.02%和0.06%。
- 肝硬化患者严重不良反应发生率(Log rank P=0.045)和死亡率(Log rank P=0.025)高于无肝硬化患者。
临床怎么用
- 作者指出DAA相关不良反应较少,贫血最常见;SOF/RBV方案不良反应发生率最高,SOF/DCV方案最低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interferon-free regimens are associated with high sustained virological response; however, associated adverse effects have yet to be fully reported. AIM: To evaluate the adverse effects associated with the different direct-acting antiviral drug (DAA) regimens in Egyptian patients. METHODS: This multicenter retrospective study included all adverse effects during and after treatment with DAA regimens of 149 816 chronic hepatitis C treated Egyptian patients. Patients received sofosbuvir (SOF)/ribavirin (RBV) (n = 21 835), SOF/simeprevir (n = 24 215) SOF/daclatasvir (DCV) (n = 58 477), SOF/DCV/RBV (n = 45 188) and paritaprevir/ombitasvir/ritonavir/RBV (n = 101). The duration of treatment varied between 12 and 24 weeks. All changes in the treatment regimens, discontinuation, mortality, and serious side effects were reported. RESULTS: Adverse effects developed in 2475 (1.7%) (mean age [54 ± 9], male gender [53%]) patients. Serious side effects developed in 68% of these patients, and SOF/RBV was the most common causing regimen (73%, P < 0.001). Anaemia and hyperbilirubinemia were the most common side effects (731/149816, 0.5% and 463/149816, 0.3%, respectively) and SOF/RBV (588/21835, 3% and 353/21835, 1.6%, respectively) showed the highest incidence in the treated patients. Hepatocellular carcinoma and mortality were reported in 0.02% and 0.06% of all treated patients, respectively. Patients with liver cirrhosis showed higher incidence of serious side effects (Log rank P = 0.045) and mortality (Log rank P = 0.025) than patients without liver cirrhosis. Male gender (P = 0.012), lower haemoglobin (P < 0.001), platelets (P < 0.001) and albumin (P = 0.001), higher bilirubin (P = 0.002) and cirrhosis (P < 0.001) were factors associated with serious side effects development. CONCLUSION: Adverse effects associated with DAAs are few, anaemia being the most common. SOF/RBV regimen showed the highest rate of side effects while SOF/DCV showed the least.
引用
- Attia D, El Saeed K, Elakel W, et al. The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients. Aliment Pharmacol Ther. 2018. PMID: 29504152. doi:10.1111/apt.14538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。